Oppenheimer Asset Management Inc. reduced its stake in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 13.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,030 shares of the company’s stock after selling 6,850 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bausch Health Companies were worth $385,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Blueshift Asset Management LLC acquired a new position in shares of Bausch Health Companies in the first quarter valued at approximately $464,000. Metis Global Partners LLC acquired a new position in Bausch Health Companies in the 1st quarter valued at $254,000. Assetmark Inc. increased its position in Bausch Health Companies by 454.3% during the 2nd quarter. Assetmark Inc. now owns 10,421 shares of the company’s stock worth $87,000 after buying an additional 8,541 shares during the period. Woodline Partners LP lifted its holdings in shares of Bausch Health Companies by 1.1% during the first quarter. Woodline Partners LP now owns 1,013,462 shares of the company’s stock worth $23,158,000 after buying an additional 10,944 shares in the last quarter. Finally, Guardian Capital Advisors LP boosted its position in shares of Bausch Health Companies by 73.8% in the first quarter. Guardian Capital Advisors LP now owns 63,690 shares of the company’s stock valued at $1,447,000 after acquiring an additional 27,040 shares during the period. 70.07% of the stock is owned by institutional investors.
Bausch Health Companies Stock Performance
NYSE:BHC opened at $6.97 on Thursday. Bausch Health Companies Inc. has a twelve month low of $4.00 and a twelve month high of $28.35. The company has a quick ratio of 0.77, a current ratio of 1.05 and a debt-to-equity ratio of 48.05. The stock’s 50-day simple moving average is $7.01 and its 200 day simple moving average is $7.90. The firm has a market capitalization of $2.52 billion, a PE ratio of 9.96, a price-to-earnings-growth ratio of 0.13 and a beta of 0.99.
Wall Street Analysts Forecast Growth
Bausch Health Companies Profile
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- International Game Technology is Well Worth the Gamble
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.